# Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

> **NCT02345265** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Fallopian Tube Carcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Ovarian Carcinoma
- Ovarian High Grade Endometrioid Adenocarcinoma
- Ovarian High Grade Serous Adenocarcinoma
- Primary Peritoneal Carcinoma
- Primary Peritoneal Endometrioid Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cediranib Maleate
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Olaparib
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02345265
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-23
- **Primary completion:** 2022-07-07
- **Final completion:** 2027-03-04
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02345265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02345265, "Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02345265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*